Zanosar

Zanosar (streptozocin) is an intravenous chemotherapy medication used primarily for pancreatic cancer treatment. This alkylating agent targets specific cancer cells while minimizing impact on healthy tissue. Always consult a healthcare professional for proper use and monitoring. Short-term storage guidance may apply per manufacturer instructions.

Zanosar is primarily used in the treatment of pancreatic neuroendocrine tumors, including pancreatic islet cell carcinoma. It may also be prescribed for other cancer types as determined by a physician. Patients often ask what Zanosar is used for when discussing treatment options with oncology teams. This medication works by interfering with cancer cell growth and division.

Common effects may include nausea, vomiting, or fatigue during treatment cycles. Some patients report changes in kidney function or blood cell counts requiring regular monitoring. These effects vary by individual and treatment duration. Always discuss any persistent or concerning symptoms with a healthcare provider promptly.

Zanosar requires careful handling by healthcare professionals due to its cytotoxic properties. Patients should inform their medical team about all current medications and health conditions before starting treatment. Regular blood tests and kidney function monitoring are typically required during therapy. Avoid exposure to the medication if pregnant or breastfeeding unless directed by a doctor.

Zanosar may interact with medications that affect liver enzymes, such as certain antibiotics or antifungals. Combining it with other chemotherapy drugs or nephrotoxic agents could increase side effects. Alcohol consumption may exacerbate nausea or other gastrointestinal effects. Always disclose all prescription, over-the-counter, and herbal products to your healthcare provider.